Immunovant, Inc. (IMVT): R&D Expense
$456.66M
Year ended 2026-03-31
$498.09M
Trailing 12 months to 2026-06-30
+41.8%
3-year compound annual growth
+46.1%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $456.66M | +26.5% | 2026-05-20, From 2025-04-01 |
| 2025-03-31 | $360.92M | +69.5% | 2026-05-20, From 2024-04-01 |
| 2024-03-31 | $212.93M | +32.9% | 2026-05-20, From 2023-04-01 |
| 2023-03-31 | $160.26M | +57.4% | 2025-05-29, From 2022-04-01 |
| 2022-03-31 | $101.81M | +48.4% | 2023-05-22, From 2021-04-01 |
| 2021-03-31 | $68.60M | +43.1% | 2022-06-08, From 2020-04-01 |
| 2020-03-31 | $47.93M | +86.2% | 2021-06-01, From 2019-04-01 |
| 2019-03-31 | $25.73M | n/a | 2020-06-29, From 2018-04-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Immunovant, Inc. (IMVT) | 2026-03-31 | $456.66M | +26.5% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $455.97M | -10.0% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $300.27M | +8.7% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $274.87M | +23.7% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $243.77M | -42.5% |
| Denali Therapeutics Inc. (DNLI) | 2025-12-31 | $418.78M | +5.6% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $116.64M | +42.1% |
| Novavax Inc (NVAX) | 2025-12-31 | $342.32M | -12.5% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $58.05M | +8.3% |
Compare IMVT, VIR, IOVA, IMCR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗